BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy by Vinay K. Pattalachinti, Emaan Haque, Mahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury, Michael Overman, Christine M. Parseghian, Van K. Morris, Bryan Kee, Ryan W. Huey, Kanwal Raghav, Colin M. Court, John Paul Shen

Get full text

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer by Al B Benson, Anirban Maitra, Milind Javle, Michael Overman, Richard E Davis, Pankaj Vats, Chandan Kumar-Sinha, Lianchun Xiao, Niharika B Mettu, Edwin R Parra, Charles D Lopez, Veerendra Munugalavadla, Priti Patel, Lin Tao, Sattva Neelapu

Get full text

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers by Akihito Kawazoe, Kohei Shitara, Chiara Cremolini, Giovanni Fucà, Sara Lonardi, Filippo Pietrantonio, Francesca Corti, Samuel J Klempner, Magali Svrcek, Thierry André, Giuseppe Curigliano, Michael Overman, Francesca Bergamo, Elisabetta Fenocchio, Massimiliano Salati, Margherita Ambrosini, Giovanni Randon, Lisa Salvatore, Romain Cohen, Raphael Colle, Maria Elena Elez, Marwan Fakih, Aakash Tushar Shah, Joseph Chao, Matthew Emmett, Marc Díez García, Giacomo Mazzoli, Leonardo Provenzano, Keigo Chida, Veronica Conca

Get full text